News & Updates
Showing Hepatology articles
Showing
Show Multimedia Only

A3 adenosine receptor agonist safe, effective for treating NAFLD
10 Nov 2021
Namodenoson, an A3 adenosine receptor (A3AR) agonist, shows clinical activity against nonalcoholic fatty liver disease (NAFLD) with or without nonalcoholic steatohepatitis (NASH), according to data from a phase II study.
10 Nov 2021
